Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Oncology Initiates $2.2M Direct Stock Offering

NEW YORK – Predictive Oncology said Thursday that it has agreed to a direct offering of 1,396,826 shares at $1.575 per share, for gross proceeds of about $2.2 million.  

The company also will issue new investors an equal number of unregistered warrants at $1.45 per share. These warrants will expire 5.5 years from issuance.  

H.C. Wainwright is the exclusive placement agent for this offering, which is priced at-market, per Nasdaq rules 

The Eagan, Minnesota-based developer of artificial intelligence and other bioinformatics technologies for precision medicine and drug discovery said that it would apply as much as $487,000 of the net proceeds to repay debts to Oasis Capital. The rest would be used as working capital. 

Formerly known as Precision Therapeutics, Predictive Oncology had another offering of $3.2 million in October when the stock was worth just $0.50 per share. 

The firm operates through three subsidiaries: Helomics, which provides tumor-analysis services for treatment personalization and new drug development; TumorGenesis, which is developing patient-derived tumor models for precision drug testing; and Skyline Medical, which markets a US Food and Drug Administration-approved system for automated medical fluid disposal. 

In mid-afternoon trading Thursday on the Nasdaq, Predictive Oncology stock was down 12 percent to $1.32. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.